First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Executive summary |
| |
| Authors: | Bernhard J Hering Emanuele Cozzi Thomas Spizzo Peter J Cowan Gina R Rayat David KC Cooper Joachim Denner |
| |
| Institution: | 1. Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, MN, USA;2. Transplant Immunology Unit, Department of Transfusion Medicine, Padua University Hospital, Padua, Italy;3. CORIT (Consortium for Research in Organ Transplantation), Padua, Italy;4. Spring Point Project, Minneapolis, MN, USA;5. Immunology Research Centre, St Vincent's Hospital, Melbourne, Vic., Australia;6. The Surgical‐Medical Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada;7. Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, USA;8. Robert Koch Institute, Berlin, Germany |
| |
| Abstract: | The International Xenotransplantation Association has updated its original “Consensus Statement on Conditions for Undertaking Clinical Trials of Porcine Islet Products in Type 1 Diabetes,” which was published in Xenotransplantation in 2009. This update is timely and important in light of scientific progress and changes in the regulatory framework pertinent to islet xenotransplantation. Except for the chapter on “informed consent,” which has remained relevant in its 2009 version, all other chapters included in the initial consensus statement have been revised for inclusion in this update. These chapters will not provide complete revisions of the original chapters; rather, they restate the key points made in 2009, emphasize new and under‐appreciated topics not fully addressed in 2009, suggest relevant revisions, and communicate opinions that complement the consensus opinion. Chapter 1 provides an update on national regulatory frameworks addressing xenotransplantation. Chapter 2 a, previously Chapter 2, suggests several important revisions regarding the generation of suitable source pigs from the perspective of the prevention of xenozoonoses. The newly added Chapter 2b discusses conditions for the use of genetically modified source pigs in clinical islet xenotransplantation. Chapter 3 reviews porcine islet product manufacturing and release testing. Chapter 4 revisits the critically important topic of preclinical efficacy and safety data required to justify a clinical trial. The main achievements in the field of transmission of all porcine microorganisms, the rationale for more proportionate recipient monitoring, and response plans are reviewed in Chapter 5. Patient selection criteria and circumstances where trials of islet xenotransplantation would be both medically and ethically justified are examined in Chapter 6 in the context of recent advances in available and emerging alternative therapies for serious and potentially life‐threatening complications of diabetes. It is hoped that this first update of the International Xenotransplantation Association porcine islet transplant consensus statement will assist the islet xenotransplant scientific community, sponsors, regulators, and other stakeholders actively involved in the clinical translation of islet xenotransplantation. |
| |
| Keywords: | porcine islets of Langerhans type 1 diabetes xenotransplantation |
|
|
